Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $56.95 | Total: $284.75 |
| 1 | 10 | $48.24 | Total: $482.40 |
| 1 | 25 | $40.87 | Total: $1,021.75 |
| 1 | 50 | $34.84 | Total: $1,742.00 |
| 1 | 100 | $30.15 | Total: $3,015.00 |
Overview
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent. CDK8-IN-12 inhibits GSK-3?, GSK-3? and PCK-? with Ki of 13 nM, 4 nM and 109 nM respectively. CDK8-IN-12 showed anti-proliferative activity against MV4-11 cells.
Chemical Properties
| Molecular Formula | C21H20ClN3O2 |
| Molecular Weight | 381.86 |
| CAS Numbers | 2613307-67-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1C2(CCN(CC2)C=3C(=CN=CC3Cl)C4=CC=5C(O4)=CC=CC5)CCN1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yu M, et al. Potent and orally bioavailable CDK8 inhibitors Design, synthesis, structure-activity relationship analysis and biological evaluation. Eur J Med Chem. 2021 ; 214 113248.